Inhibition of farnesyl protein transferase - A review of the recent patent literature

IDrugs

Volumn 4, Issue 12, 2001, Pages 1382-1388

  Doll, Ronald J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1242268974     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Fahraeus R, Fischer P, Krausz E, Lane DP: New approaches to cancer therapies. J Pathol (1999) 187:138-146.
2. Bos JL: Ras oncogenes In human cancer: a review. Cancer Res (1989)49:4682-4689.
3. Bollag G, McCormick F: Regulators and effectors of ras proteins. Annu Rev Cell Biol (1991) 7:601-632.
4. Barbacid M: Ras genes. Annu Rev Biochem (1987) 56:779-827.
5. Casey PJ: Biochemistry of protein prenylation. J Lipld Res (1992) 33:1731-1740.
6. Reiss Y. Stradley SJ, Geirasch LM, Brown MS, Goldstein JL Sequence requirement for peptide recognition by rat brain ras p21 protein farnesyl transferase. ProcNatlAcadSciUSA (1991) 88:732-736.
7. Sinensky M, Lutz RJ: The prenylation of proteins. Bioessays (1992) 14:25.
8. Kalo K, Cox AD, Hisaka MM, Grahm SM, Buss JE, Der CJ: Isoprenoid addition to ras protein Is the critical modification for Its membrane association and transforming activity. Proc Natl Acad Sei USA (1992)89:6403-6407.
9. Sepp-Lorenzino L, Ma Z, Rands E, Kohl N E, Gibbs J B, -Oliff A, Rosen N: A peptidomimetic inhibitor of farnesyhprotein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res (1995) 55(22):5302-5309.
10. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Grahm SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science ( 1993) 260: 1934-1937.
11. Kohl N E, Wilson F R, Mosser SD Giuliani E, DeSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee T-J, Smith RL, Grahm SL, Hartman GD, Gibbs JB, Oliff A: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Nail AcadSei(75/1(1994) 91:9141-9145.
12. Gibbs JB, Graham SL, Hartman GD, Koblan KS, Kohl NE, Orner ÇA, Oliff A: Farnesyltranferase inhibitors versus ras Inhibitors. Curr Opin Chem Biol ( 1997) 1:197-203.
13. Rowinsky EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Onco/(1999) 17:3631-3652.
14. Ashar HR, Armstrong L, James U, Carr DM, Gray K, Taveras A, Doll RJ, Bishop WR, Kirschmeier P T: Biological effects and mechanism of action of farnesyl transferase inhibitors. Chem Res Toxicol (2000) 13:949-952.
15. Ayral-Kaloustian S, Skotnicki JS: Ras farnesyltransferase inhibitors. Annu Rep Med Chem (1996) 31:171 -180.
16. End DW: Farnesyl protein transferase inhibitors and other therapies targeting the ras signal transduction pathway. Investigational New Drugs (1999) 17:241-258. • A good discussion of how Ras and FPT fit into the signal transduction process.
17. Williams TM, Dinsmore CJ: Farnesyltransferase inhibitors: design of a new class of cancer chemotherapeutic agents. Adv Med Chem (1999)4:273-314. • A good discussion on the historical development of FPT inhibitors.
18. Lamothe M, Perez M: Recent progress in protein farnesyltransferase inhibition. IDrugs (2000) 3:1336-1345.
19. Rowinsky EK, Patnaik A: The development of protein farnesyltransferase and other ras-directed therapeutics for malignant diseases. Emerging Drugs (2000) 5:161-199.
20. Patnaik A, Rowinsky E K: Early clinical experience with farnesyl protein transferase inhibitors. In: Famesyltransferase inhibitors in cancer therapy (2001). Sebti SM, Hamilton AD (Eds), Humana Press, Totowa, NJ (2001): 233-249.
21. Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Wat/ Cancer Inst (2001) 93:1062-1074
22. Soignet S, Yao S-L, Britten C, Spriggs D, Pezzulli S, McCreery H, Mazina K, Deutsch P, Lee Y, Lobell R, Rosen N, Rowinsky E: Pharmacokinetics and pharmacodynamics of the farnesyl protein transferase inhibitor (L-778,123) in solid tumors. A AC R. (1999) 90th (Philadelphia): Abs 3413
23. Britten CD, Rowinsky E, Yao S-L, Rosen N, Eckhardt SG, Drengler R, Hammond L, Siu LL, Smith L, McCreery H, Pezzulli S, Lee Y, Lobell R, Deutsch P, Von Hoff D, Spriggs D: The farnesyl protein transferase (FPTase) inhibitor L-778,123 in patients with solid tumors. ASCO. (1999) 35th (Atlanta): Abs 597.
24. Gibbs JB, Anthony NJ, Buser CA, deSolms SJ, Graham SL, Hartman GD, Heimbrook DC, Lobell RB, Koblan KS, Kohl NE, Williams TM: Farnesyltransferase inhibitors as potential anticancer agents. ACS (2000) 219th (San Francisco): MEDI 292.
25. Williams TM, Dinsmore MJ, Bogusky JM, Bergman JM, Nguyen DN, Stump CA, Zartman CB, Busher CA, Huber DD, Koblan KS, Kohi NE, Lobell RB, Kassahun K, Rodrigues DD, Gibbs JB, Heimbrook DC, Hartman GD, Huff JR, Graham SL: Macrocycle and other constrained analogues of the FTIL-778123. /CS(2001) 222nd (Chicago): MED11.
26. End D, Skrzat SG, Devine A, Angibaud P, Venet M, Sanz G, Bowden C: R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI): biochemical and cellular effects in H-ras and K-ras dominant systems. AACR (1998) 89th (New Orleans): Abs 1847. .
27. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Vemet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 In vivo and in vitro. Cancer Res (2001) 61:131-137.
28. Holden SN, Cohen R, Persky M, Mikule C, Morrow M, Richards H, Rodriguez S, Eckhardt, SG: A Phase I pharmacological and biological study of the farnesyl transferase inhibitor (FTI) R115777 and capecitabine in patients (pts) with advanced solid malignancies. MCI EORTC Symp New Drugs Cancer Ther (2000) 11:533.
29. Johnson SR, Ellis PA, Houston S, Hickish T, Howes AJ, Palmer P, Horak I: A phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced breast cancer. ASCO (2000) 36th (New Orleans): 318..-
30. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt PB, Kremer AB, Cowan KH: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R11577 in advanced cancer. J Clin Onco/(2000) 18:927-941.
31. Venet, M: R115777 as farnesyl protein transferase inhibitor: synthesis and SAR. /ACS (2001) 222nd (Chicago):MEDI 5.
32. Njoroge FG, Taveras AG, Kelly J, Remiszewski S, Mallams AK, Wolin R, Afonso A, Cooper AB, Rane DF, U'u Y-T, Wong J, Vibulbhan B, Pinto P, Deskus J, Alvarez CS, del Rosario J, Connolly M, Wang J, Desai J, Rossman RR, Bishop WR, Patton R, Wang L, Kirschmeier P, Bryant MS, Nomeir AA, Un C-C, Liu M, McPhail AT, Doll RJ, Girijavallabhan VM, Ganguly AK: (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro5H-benzo[5,6]cyclohepta[1,2-b]- pyridin-11 (R)-yl)-1 -piperidinylJ-2oxo-ethyl]-1-piperidinecarboxamlde (SCH-66336): A very potent farnesyl protein transferase inhibitor as a novel antitumor agent J Med Chem (1998) 41:4890-902.
33. Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske AR, Piccart M: Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol (2001 ) 15:1167-1175.
34. Kirn E, Glisson BS, Meyers ML, Herbst RS, Shin DM, Statkevich P, Bangert S, Hong WK, Khuri FR: A Phase l/ll study of the farnesyl transferase inhibitor (FD) SCH66336 with Paclitaxel in patients with solid tumors. AACR (2001) 92nd (New Orleans): Abs 2629.
35. Hunt JT, Ding CZ, Batorsky R, Bednarz M, Bhide R, Cho Y, Chong S, Chao S, Gullo-Brown J, Guo P, Kirn SH, Lee RYF, Leftheris K, Miller A, Mitt T, Patel M, Penhallow BA, Ricca C, Rose WC, Schmidt R, Slusarchyk WA, Vite G, Manne V: Discovery of (R)-7-cyano2,3,4,5-tetrahydro-1-(1W-imidazol-4-ylmethyl)-3-(phenylmethyl)4-(2- thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent anti-tumor activity. J Med Chem (2000) 43: 3587-3595.
36. Mackay HJ, Hoekstra R, Eskens F, Devlin M, Sonnicchsen D, Voi M, Evans TR, Van Vreckem A, Verweij J: A Phase I dose escalating study of BMS-214662 in combination with cisplatin in patients with advanced solid tumors. ASCO (2001) 37th (San Francisco): Pt 1,315.
37. Camacho LH, Soignet SL, Pezzulli S, Canales C, Aghajanian C, Spriggs DS, Damie B, Sonnichsen D: Dose escalation study of oral farnesyl transferase inhibitor (FTI) BMS-214662 with solid tumors. ASCO (2001) 37th (San Francisco): Pt 1, 311.
38. Voi M, Tabemero J, Cooper MR, Marimon I, Van Verckem A, Albanell J, Valverde S, Carreras J, Baselga J: A Phase I study of the farnesyltransferase (FT) inhibitor BMS-214662 administered as a weekly 1-hour infusion in patients with solid tumors: Clinical findings. /1SCO(2001) 37th (San Francisco):?l 1, 312.
39. Kim KB, Shin DM, Summey CC, Kurie JM, Fossella FV, Lee JS, Zinner RG, Glisson BS, Kies MS, Hong WK, Abbaizzese JL, Khuri FR: Phase I study of farnesyl transferase inhibitor, BMS-214662 in solid tumors. ASCO (2001) 37th (San Francisco): Pt 1, 313.
40. Bailey HH, Mamocha R, Arzoomanian R, Alberti D, Binger K, Volkman J, Feierabend C, Ellingen S, Black S, Hampton K, Cooper M et at Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. ASCO (2001) 37th (San Francisco): Pt 1,314.
41. Tabemero J, Sonnichsen D, Albanell J, DamieB, Rojo F; Christopher L, Marimon I, Dendler R, Trigo JM, Manne S, Garcia M et ah A phase I pharmacokinetic (PK) and serial tumor and PBMC pharmacodynamic study of weekly BMS-214662, a farnesyltransferase (FT) Inhibitor, in patients with advanced solid tumors. ASCO (2001) 37th (San Francisco): Pt 1, 304.
42. Baudoin B, Brealy B, Clerc J-C, Dereu N, El Ahmad Y et at. High throughput organic synthesis, crystallography and early ADME integration applied to the discovery of potent and orally bioavailable chromane and benzoxazine farnesyltransferase inhibitors. ACS (2001) 222nd (Chicago):MEDI 4.
43. Taveras AG, Chao J, Aki C, Cooper AB, Strickland C, Gray K, Patton R, Kirschmeier P, Liu M, Nomeir A, Doll RJ, Girijavallabhan VM: SCH66336 and beyond: discovering next generation inhibitors of farnesyl protein transferase. ACS (2001) 222nd (Chicago):MEDI 3.
44. Yokoyama K, Trobridge P, Buckner FS, Schölten J, Stuart KD, Van Voorhis WC, Gelb MH: The effects of protein farnesylation inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth. MolBiochem Parasitol (1998) 94: 87-97. References to patent literature
45. MERCK & Co INC (McGlynn MW, Asghamejad M): Sustained release drug dispersion delivery device. WO-00105430 (2001).
46. MERCK & Co INC (Varsdona RJ, McCauley JA): Crystal forms of 1-{3-chlorophenyl)-4-[1-(4-cyanobenzyr)-5-iiTiidazorylmettiyl}-2-piperazinone. WO-00107437 (2001).
47. MERCK & Co INC (Dinsmore CJ, Huff JR, Zartman CB): Prenyl protein transferase inhibitors. WO-00107051 (2001).
48. MERCK & Co INC (Dinsmore CJ, Graham SL, Williams TM): Prenyl protein transferase inhibitors. WO-00107046 (2001).
49. MERCK & Co INC (Dinsmore CJ, Graham, SL, Williams TM): Inhibitors of prenyl-protein transferase. WO-00117992 (2001).
50. MERCK & Co INC (Huffman, JM): Inhibitors of prenyl-protein transferase. WO-00145704 (2001).
51. MERCK & Co INC (Huffman JM): Inhibitors of prenyl proteintransf erase. WO-00145707 (2001).
52. MERCK & Co INC (Bell IM, Gallicchio SN, Beshore DC, Zartman CB): Inhibitors of prenyl protein-transferase. WO-00118006 (2001).
53. MERCK & Co INC (Desolms SJ, MacTough SC, Shaw AW): Inhibitors of prenyl protein-transferase. WO-001151125 (2001).
54. MERCK & Co INC (Desolms SJ, MacTough SC, Shaw AW): Inhibitors of prenyl protein-transferase. WO-001151126 (2001 ).
55. MERCK & Co INC (Desolms SJ, Stokker GE, Shaw AW): Inhibitors of prenyl protein-transferase. WO-001151127 (2001).
56. MERCK & Co INC (Desolms SJ, Shaw AW): Inhibitors of prenyl protein-transferase. WO-001151128 (2001).
57. MERCK & Co INC (Dinsmore CJ): Inhibitors of prenyl protein-transferase. WO-001151494 (2001).
58. AVENTIS PHARMA SA (Baudoin B, Jimonet P, Laoui A): Novel 8-carbonyl chroman derivatives, preparation and therapeutic use thereof. WO-00109112(2001).
59. AVENTIS PHARMA SA (Baudoin B, Jimonet P): Novel 8-carbamyl chroman derivatives, preparation and therapeutic use thereof. WO-00109124 (2001).
60. AVENTIS PHARMA SA (Baudoin B, Jimonet P, Maignan S, Achard D, Mailliet P, Laoui A, Nemecek C): Novel 8-carbonyl chroman derivatives, preparation and therapeutic use thereof. WO-00109125 (2001).
61. AVENTIS PHARMA SA (Achard D, Jimonet P, Mailliet P, Sabuco J-F): Benzoxazine derivatives and their therapeutic use. WO-00109127 (2001).
62. PFIZER PRODUCTS INC (Yang BV): Quinoline derivatives useful for inhibiting farnesyl protein transferase. EP-01106612 (2001).
63. PFIZER PRODUCTS INC (Yang BV): Anticancer compound and enantiomer separation method useful for synthesizing said compound. WO-00153289 (2001).
64. PFIZER PRODUCTS INC (Yang BV): Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents. WO-00047574 (2000).
65. SCHERING CORPORATION (Afonso A, Baldwin JJ, Doll RJ, Li G, Mallams AK, Njoroge FG, Pane DF, Reader JC, Rossman RR): Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferate diseases. US-06214827 (2001).
66. SCHERING CORPORATION (Cooper AB, Desai JA, Saksena AK, Girijavallabhan VM, Wang JJ-S): Compounds useful for inhibition of farnesyl protein transferase. US-06225322 (2001).
67. SCHERING CORPORATION (Bishop WR, Doll RJ, Mallams AK, Njoroge FG, Pétrin JM, Piwinski JJ, Wolin RL, Taveras AG, Remiszewski SW): Tricyclic amide and urea compounds useful for Inhibition of Gprotein function and for treatment of proliferative diseases. US06242458 (2001).
68. SCHERING CORPORATION (Doll RJ, Kelly MK, Mallams AK, Njoroge FG, Remiszewski SW, Taveras AG): Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases. US-06214828 (2001).
69. SCHERING CORPORATION (Remiszewski SW, Doll RJ, Alvarez C, Lalwani T): Compounds useful for inhibition of farnesyl protein transferase. US-06211193 (2001).
70. SCHERING CORPORATION (Njoroge FG, Taveras AG, Doll RJ, Lalwani T, Alvarez C, Remiszewski SW): Compounds useful for inhibition of farnesyl protein transferase. US-06228856 (2001).
71. SCHERING CORPORATION (Doll RJ, Alvarez C, Lalwani T, Liu Y-T): Compounds useful for inhibition of farnesyl protein transferase. US-06228865 (2001).
72. SCHERING CORPORATION (Cooper AB, Doll RJ, Saksena AK, Girijavallabhan VM): Compounds useful for inhibition of farnesyl protein transferase. US-06239140 (2001).
73. SCHERING CORPORATION (Guzi T, Rane DF, Mallams AK, Cooper AB, Doll RJ, Girijavallabhan VM, Kelly JM, Chao J): Farnesyl protein transferase inhibitors. WO-00037458 (2000).
74. SCHERING CORPORATION (Taveras AG, Doll RJ, Cooper AB, Ferriera JA, Guzi T, Mallams AK, Rane DF, Girijavallabhan VM, Afonso A et at): Tricyclic farnesyl protein transferase inhibitors. WO-00037459 (2000).
75. BRISTOL-MYERS SQUIBB Co (Raghavan KS, Malloy TM, Varia SA): Complexes of ras-farnesyltransferase inhibitor and sulfobutylether-7β-cyclodextrin or 2-hydroxypropyl-βcyclodextrin and method. WO-00042849 (2000).
76. BRISTOL-MYERS SQUIBB Co (Chen B-C, Sundeen JE, Guo P): Reductive alkylation of secondary amines with hydrosilane. US-06100395 (2000).
77. IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY & MEDICINE (Field MC, Ali BRS): Protein farnesyl transferase inhibitor, antiparasitic. WO00105384(2001).
78. RlJKSUNIVERSITEIT LEIDEN, NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELUK ONDERZOEK (Burm BEA, Voskuyl N, van den Elst H, Pieterman EJ, Cohen LH, Overhand M, van der Marel GA, van Boom JH): Novel inhibitors of prenylated pyrophosphate consuming enzymes. EP-01090909 (2001).
79. JANSSEN PHARMACEUTICA NV (Sana AK, End DW, De Corte BLD, Breslin HJ, Liu L): Triazoles as farnesyl transferase inhibitors. WO00136395(2001).
80. US DEPARTMENT OF HEALTH & HUMAN SERVICES (Clark G, Zujewski J): Compositions and methods for treatment of breast cancer. WO00145740 (2001).